Greg Kellogg
Papers
1
Total Citations
4
H-Index
1
About
Greg Kellogg is a pioneering figure in the field of microfluidic assay development for drug discovery, with a focused expertise in advancing automated, miniaturized platforms for ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) screening. His most cited work, "ADMET Assays on Tecan's LabCD-ADMET System," demonstrates his significant contribution to integrating centrifugal microfluidics with critical preclinical testing. Kellogg’s research centered on translating complex biological assays—specifically Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—onto a compact, spinning disc format. This innovation aimed to streamline the drug development pipeline by enabling higher throughput and reduced reagent consumption for early-stage compound evaluation. While his foundational paper has accumulated 4 citations, its true impact lies in its role as a proof-of-concept for lab-on-a-disc technologies, influencing subsequent generations of microfluidic ADMET tools. Kellogg’s work remains a notable early achievement in the quest to create more efficient, integrated systems for pharmacokinetic profiling, bridging the gap between traditional benchtop methods and modern, high-throughput microfluidic solutions.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003